CAMBRIDGE, Mass.--(BUSINESS WIRE)--sphingotec GmbH, headquartered in Hennigsdorf, Germany with U.S. operations in Cambridge, Massachusetts, today announced that it has out-licensed two of its biomarker assays—sphingotest® pro-NT and sphingotest® pro-ENK—to GeneNews Limited (TSX:GEN). The biomarker assays will aid physicians in risk assessment for breast cancer in females in the general population. sphingotec discovers and develops blood tests to detect cancer, cardiovascular conditions and kidney disease in high-risk patients.
Help employers find you! Check out all the jobs and post your resume.
